Zakarija Anaadriana, Kwaan Hau C
Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611-3008, USA.
Expert Rev Cardiovasc Ther. 2003 Jul;1(2):271-81. doi: 10.1586/14779072.1.2.271.
There is an increased risk not only of bleeding but also of thrombosis in the cancer patient. The double jeopardy creates an additional problem in their management and requires special attention. This review provides information on pathophysiology in the regulation of hemostasis, leading to bleeding and thrombotic complications. The process is complex with multiple factors being involved. In addition to the pathogenesis, a number of clinical syndromes, diagnostic methods and the management of hemostatic abnormalities in the cancer patient are presented. Potential effects of cancer treatment on these risks magnify the hazards encountered by the managing team. Wherever management is discussed, emphasis is placed on the scientific basis for the rationale of the therapeutic approach.
癌症患者不仅有出血风险增加的情况，还有血栓形成风险。这种双重风险给他们的治疗带来了额外问题，需要特别关注。本综述提供了关于止血调节的病理生理学信息，这些信息会导致出血和血栓形成并发症。该过程很复杂，涉及多种因素。除了发病机制外，还介绍了一些临床综合征、诊断方法以及癌症患者止血异常的治疗。癌症治疗对这些风险的潜在影响放大了治疗团队所面临的危害。无论何处讨论治疗，重点都放在治疗方法原理的科学依据上。
